AMENDMENT NO. 2 TO THAT CERTAIN DEVELOPMENT AND EXCLUSIVE LICENSE AGREEMENTDevelopment and Exclusive License Agreement • May 2nd, 2014 • Zenosense, Inc. • Gold and silver ores
THIS AMENDMENT NO. 2, dated as of April 28, 2014 (the “Amendment”), to that certain AGREEMENT dated as of November 26, 2013, as previously amended December 4, 2013 (the “Agreement”), among Sgenia Soluciones, S.L. (“Soluciones”), ZENON Biosystem, S.L. (“Subco”), Sgenia Industrial, S.L. (“Sgenia”), the parent corporation of its subsidiaries, Soluciones and Subco, and Zenosense, Inc., formerly Braeden Valley Mines, Inc. (the “Company”), is hereby being amended to include further licensing of cancer sensory devices.
1 Exhibit 10.20 DEVELOPMENT AND EXCLUSIVE LICENSE AGREEMENT This DEVELOPMENT AND EXCLUSIVE LICENSE AGREEMENT, effective this 10th day of December 1996 (hereinafter "Agreement"), is by and between Chugai Pharmaceutical Co., Ltd., a Japanese corporation...Development and Exclusive License Agreement • March 31st, 1998 • Gliatech Inc • Biological products, (no disgnostic substances)
AMENDMENT NO. 1 TO THAT CERTAIN DEVELOPMENT AND EXCLUSIVE LICENSE AGREEMENTDevelopment and Exclusive License Agreement • December 6th, 2013 • Zenosense, Inc. • Gold and silver ores
THIS AMENDMENT NO. 1, dated as of December 4, 2013 (the “Amendment”), to that certain AGREEMENT dated as of November 26, 2013 (the “Agreement”), among Sgenia Soluciones, S.L. (“Soluciones”), ZENON Biosystem, S.L. (“Subco”) and Zenosense, Inc., formerly Braeden Valley Mines, Inc. (the “Company”), is hereby being amended to include as an additional party, Sgenia Industrial, S.L. (“Sgenia”), the parent corporation of its subsidiaries, Soluciones and Subco, and formed under the laws of the Kingdom of Spain, and to acknowledge that the operative date of the Agreement shall be the date of this Amendment; provided however, all the parties hereto acknowledge that the funding obligations of the initial payment by the Company have been fully met.
AMENDMENT NO. 3 TO THAT CERTAIN DEVELOPMENT AND EXCLUSIVE LICENSE AGREEMENTDevelopment and Exclusive License Agreement • July 24th, 2014 • Zenosense, Inc. • Gold and silver ores
THIS AMENDMENT NO. 3, dated as of July 21, 2014 (the “Amendment No. 3”), to that certain AGREEMENT dated as of November 26, 2013, as previously amended December 4, 2013 and on April 23, 2014 (the “Agreement”), among Sgenia Soluciones, S.L. (“Soluciones”), ZENON Biosystem, S.L. (“Subco”), Sgenia Industrial, S.L. (“Sgenia”), the parent corporation of its subsidiaries, Soluciones and Subco, and Zenosense, Inc. (together the Sgenia Parties”) and Zenosense Inc., formerly Braeden Valley Mines, Inc. (the “Company”), is hereby being amended to modify the budgeting and financing for the research and development of the MRSA/SA and cancer sensory devices.
DEVELOPMENT AND EXCLUSIVE LICENSE AGREEMENTDevelopment and Exclusive License Agreement • December 6th, 2013 • Zenosense, Inc. • Gold and silver ores • New York
AGREEMENT, dated as of November 26, 2013, among Sgenia Solutiones, S.L. (“Sgenia”), ZENON Biosystem, S.L. (“Subco”), a subsidiary wholly owned by Sgenia, both of which are formed under the laws of Spain, and Braeden Valley Mines Inc., a Nevada corporation (the “Company”).
DEVELOPMENT AND EXCLUSIVE LICENSE AGREEMENTDevelopment and Exclusive License Agreement • September 19th, 2023 • Dyadic International Inc • Biological products, (no disgnostic substances)
This DEVELOPMENT AND EXCLUSIVE LICENSE AGREEMENT (“Agreement”) is made as of September 18, 2023 (the “Effective Date”) by and between Dyadic International (USA), Inc., a corporation having a place of business at 140 Intracoastal Pointe Drive, Suite 404, Jupiter, FL 33477-5094 (“Licensor”), and INZYMES ApS, a corporation having a place of business at Strandvejen 60, 2900 Hellerup, Denmark (“Licensee”). Licensor and Licensee are each referred to herein as such or, individually, as a “Party” or, collectively, as “Parties.”
